Dragon Pharmaceutical Inc. DRUG 深 滬
等待開盤 09-20 09:30:00 美东时间
1.2437
-0.006
-0.50%
華盛通- 最 高1.30
- 今 開1.30
- 成交量 4.31万股
- 最 低 1.1501
- 昨 收 1.25
- 總市值 555.15万
- 52周最高 2.39
- 市盈率 靜 --
- 換手率 0.96%
- 52周最低 0.93
- 委 比 81.88%
- 總股本 446.37万
- 歷史最高 44.75
- 量 比 1.43
- 振 幅 11.99%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bright Minds Trials New Epilepsy Drug in Phase 2
Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosci...
09-13 01:09
Medical journal retracts three articles related to MDMA for PTSD
The journal Psychopharmacology on Aug. 10 retracted three articles related to the use of MDMA for PTSD, the day after the U.S. FDA rejected the use of the psychedlic drug for the condition. Scientists...
08-12 23:50
'Zepbound Sheds More Weight Than Wegovy, Study Finds' - Forbes
https://www.forbes.com/sites/roberthart/2024/07/08/zepbound-sheds-more-weight-than-wegovy-study-finds/Eli Lilly's popular obesity injection Zepbound trounces Novo Nordisk's Wegovy when it comes to shedding weight,
07-08 23:21
Psychedelic stocks mixed as FDA comments on MDMA therapy
Companies focused on psychedelic medicines indicated a mixed performance on Friday after the U.S. FDA commented on Lykos Therapeutics' marketing application for midomafetamine (MDMA), also known as ec...
05-31 22:43
CSPC PHARMACEUTICAL(1093.HK):ACCELERATING GROWTH IN FINISHED DRUG SALES
Strong double-digit growth in 1Q24. CSPC reported 1Q24 revenue of RMB8.98bn (+1...
05-28 19:17
Bright Minds Biosciences Reports Financial Downturn
Bright Minds Biosciences Inc. (TSE:DRUG) has released an update. Bright Minds B...
05-17 18:58
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy
05-07 23:54
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Findings From Tezspire® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS® (avacopan) Data in Adults ...
05-01 19:00
Psychedelic drug developers could benefit from NIH funding for chronic pain
The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, s...
04-30 01:37
